Why the study?
Does dexrazoxane reduce cardiotoxicity in patients with advanced breast cancer receiving doxorubicin-containing therapy?
Does dexrazoxane reduce cardiotoxicity in patients with advanced breast cancer receiving doxorubicin-containing therapy?
Dexrazoxane is the first agent shown to significantly reduce doxorubicin-induced cardiotoxicity in patients with advanced breast cancer.
No takes yet. Share an insight, caveat, or question.
Supports dexrazoxane for cardioprotection with doxorubicin in advanced breast cancer; extends evidence without compromising progression or survival.
Swain et al. (1997) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: